Abivax (AAVXF) Non-Current Deferred Tax Liability (2023 - 2025)

Abivax has reported Non-Current Deferred Tax Liability over the past 3 years, most recently at $20.5 million for Q4 2025.

  • Quarterly results put Non-Current Deferred Tax Liability at $20.5 million for Q4 2025, up 1111.46% from a year ago — trailing twelve months through Dec 2025 was $20.5 million (up 1111.46% YoY), and the annual figure for FY2025 was $19.9 million, up 1060.9%.
  • Non-Current Deferred Tax Liability for Q4 2025 was $20.5 million at Abivax, up from $1.7 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for AAVXF hit a ceiling of $20.5 million in Q4 2025 and a floor of $477717.3 in Q4 2023.
  • Median Non-Current Deferred Tax Liability over the past 3 years was $1.7 million (2024), compared with a mean of $7.6 million.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: skyrocketed 254.32% in 2024 and later surged 1111.46% in 2025.
  • Abivax's Non-Current Deferred Tax Liability stood at $477717.3 in 2023, then skyrocketed by 254.32% to $1.7 million in 2024, then surged by 1111.46% to $20.5 million in 2025.
  • The last three reported values for Non-Current Deferred Tax Liability were $20.5 million (Q4 2025), $1.7 million (Q4 2024), and $477717.3 (Q4 2023) per Business Quant data.